Drug-Drug Interaction Study of Mitiglinide and Gemfibrozil
Primary Purpose
Type 2 Diabetes Mellitus
Status
Completed
Phase
Phase 1
Locations
Study Type
Interventional
Intervention
placebo for gemfibrozil
gemfibrozil
Sponsored by

About this trial
This is an interventional treatment trial for Type 2 Diabetes Mellitus
Eligibility Criteria
Inclusion Criteria:
- non-smoker
- Body mass index (BMI) of 19-28 kg/m2
- no relevant food allergies
Exclusion Criteria:
- any subject for whom gemfibrozil is contraindicated
- any subject with a history of hypoglycemia or who tend to get easily hypoglycemic
- clinically significant history of or current abnormality or disease of any organ system
Sites / Locations
Arms of the Study
Arm 1
Arm 2
Arm Type
Experimental
Placebo Comparator
Arm Label
2
1
Arm Description
mitiglinide + gemfibrozil
mitiglinide + placebo for gemfibrozil
Outcomes
Primary Outcome Measures
pharmacokinetics of mitiglinide
pharmacodynamics of mitiglinide
Secondary Outcome Measures
safety and tolerance of mitiglinide when co-administered with 600 mg gemfibrozil
Full Information
NCT ID
NCT00566865
First Posted
December 3, 2007
Last Updated
February 16, 2009
Sponsor
Elixir Pharmaceuticals
1. Study Identification
Unique Protocol Identification Number
NCT00566865
Brief Title
Drug-Drug Interaction Study of Mitiglinide and Gemfibrozil
Official Title
A Double-Blind, Placebo-Controlled Study to Assess the Effect of Gemfibrozil Co-Administration on the Pharmacokinetics and Pharmacodynamics of Mitiglinide in Healthy Volunteers
Study Type
Interventional
2. Study Status
Record Verification Date
February 2009
Overall Recruitment Status
Completed
Study Start Date
November 2007 (undefined)
Primary Completion Date
December 2007 (Actual)
Study Completion Date
December 2007 (Actual)
3. Sponsor/Collaborators
Name of the Sponsor
Elixir Pharmaceuticals
4. Oversight
Data Monitoring Committee
No
5. Study Description
Brief Summary
The primary objective of this study is to determine the extent of effect of gemfibrozil on the pharmacokinetics and pharmacodynamics of mitiglinide.
6. Conditions and Keywords
Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Type 2 Diabetes Mellitus
7. Study Design
Primary Purpose
Treatment
Study Phase
Phase 1
Interventional Study Model
Crossover Assignment
Masking
ParticipantCare ProviderInvestigatorOutcomes Assessor
Allocation
Randomized
Enrollment
14 (Actual)
8. Arms, Groups, and Interventions
Arm Title
2
Arm Type
Experimental
Arm Description
mitiglinide + gemfibrozil
Arm Title
1
Arm Type
Placebo Comparator
Arm Description
mitiglinide + placebo for gemfibrozil
Intervention Type
Drug
Intervention Name(s)
placebo for gemfibrozil
Intervention Description
mitiglinide + placebo for gemfibrozil 600 mg bid
Intervention Type
Drug
Intervention Name(s)
gemfibrozil
Intervention Description
Mitiglinide + 600 mg gemfibrozil bid
Primary Outcome Measure Information:
Title
pharmacokinetics of mitiglinide
Time Frame
3 days of treatment with gemfibrozil
Title
pharmacodynamics of mitiglinide
Time Frame
3 days of treatment with gemfibrozil
Secondary Outcome Measure Information:
Title
safety and tolerance of mitiglinide when co-administered with 600 mg gemfibrozil
Time Frame
3 days of treatment with gemfibrozil
10. Eligibility
Sex
All
Minimum Age & Unit of Time
18 Years
Maximum Age & Unit of Time
55 Years
Accepts Healthy Volunteers
Accepts Healthy Volunteers
Eligibility Criteria
Inclusion Criteria:
non-smoker
Body mass index (BMI) of 19-28 kg/m2
no relevant food allergies
Exclusion Criteria:
any subject for whom gemfibrozil is contraindicated
any subject with a history of hypoglycemia or who tend to get easily hypoglycemic
clinically significant history of or current abnormality or disease of any organ system
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Erin Nulf, RN, BSN
Organizational Affiliation
Quintiles Phase I Services
Official's Role
Study Director
12. IPD Sharing Statement
Learn more about this trial
Drug-Drug Interaction Study of Mitiglinide and Gemfibrozil
We'll reach out to this number within 24 hrs